Last reviewed · How we verify

NCT04126005

Natural History Study of Patients With Canavan Disease (CANinform Study)

Completed Last updated 17 April 2026
What this trial tests

trial in Canavan Disease in 67 participants. Completed in 31 August 2025.

Timeline
10 October 2019
Primary endpoint
21 May 2025
31 August 2025

Quick facts

Lead sponsorAspa Therapeutics
StatusCompleted
Study typeOBSERVATIONAL
Enrollment67
Start date10 October 2019
Primary completion21 May 2025
Estimated completion31 August 2025
Sites3 locations across United States, Germany

Conditions studied

Sponsor

Aspa Therapeutics — full company profile →

Who can join

Eligibility, any sex, with Canavan Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study uses medical records that allow retrospective data extraction of critical milestone and motor function data. In addition, prospective assessments collect data relevant to the natural history of Canavan disease in children.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Urine <i>N</i>-Acetylaspartate Distinguishes Phenotypes in Canavan Disease.
    Nagy A, Eichler F, Bley A, Bredow J, et al · · 2024 · cited 3× · PMID 39628365 · DOI 10.1089/hum.2024.168

Verify or expand the search:

Other recruiting trials for Canavan Disease

Currently open trials in the same condition.

Other Aspa Therapeutics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04126005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing